CMG Pharmaceutical Co. Ltd (058820) — Cash Flow-to-Debt Ratio
CMG Pharmaceutical Co. Ltd (058820) has a Cash Flow-to-Debt Ratio of -0.04x as of December 2025, meaning its operating cash flow of ₩-4.08 Billion could theoretically repay 0% of its total liabilities (₩104.41 Billion) in one year. See 058820 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CMG Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for CMG Pharmaceutical Co. Ltd across 12 annual periods. Also explore 058820 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for CMG Pharmaceutical Co. Ltd (2014–2025)
Year-by-year debt coverage analysis for CMG Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see CMG Pharmaceutical Co. Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | ₩-11.02 Billion | ₩104.41 Billion | ▼ -4244.1% |
| 2024 | 0.00x | ₩290.09 Million | ₩113.89 Billion | ▼ -96.6% |
| 2023 | 0.08x | ₩3.91 Billion | ₩51.87 Billion | ▼ -56.8% |
| 2022 | 0.17x | ₩4.94 Billion | ₩28.31 Billion | ▼ -55.2% |
| 2021 | 0.39x | ₩5.63 Billion | ₩14.47 Billion | ▲ +87.9% |
| 2020 | 0.21x | ₩2.94 Billion | ₩14.22 Billion | ▼ -11.4% |
| 2019 | 0.23x | ₩2.82 Billion | ₩12.08 Billion | ▲ +173.9% |
| 2018 | 0.09x | ₩886.78 Million | ₩10.40 Billion | ▼ -49.1% |
| 2017 | 0.17x | ₩1.95 Billion | ₩11.62 Billion | ▼ -28.3% |
| 2016 | 0.23x | ₩2.31 Billion | ₩9.87 Billion | ▼ -5.7% |
| 2015 | 0.25x | ₩2.41 Billion | ₩9.73 Billion | ▲ +210.0% |
| 2014 | 0.08x | ₩724.89 Million | ₩9.07 Billion | — |